ES2577390T3 - Dispositivos de administración transmucosa con mayor captación - Google Patents
Dispositivos de administración transmucosa con mayor captación Download PDFInfo
- Publication number
- ES2577390T3 ES2577390T3 ES07796992.1T ES07796992T ES2577390T3 ES 2577390 T3 ES2577390 T3 ES 2577390T3 ES 07796992 T ES07796992 T ES 07796992T ES 2577390 T3 ES2577390 T3 ES 2577390T3
- Authority
- ES
- Spain
- Prior art keywords
- fentanyl
- polymeric diffusion
- otfc
- devices
- diffusion medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003232 mucoadhesive effect Effects 0.000 abstract description 31
- 238000009792 diffusion process Methods 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 23
- 210000004877 mucosa Anatomy 0.000 abstract description 15
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract description 14
- 230000004888 barrier function Effects 0.000 abstract description 13
- 229960001736 buprenorphine Drugs 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 33
- 229920000642 polymer Polymers 0.000 description 32
- 229960002428 fentanyl Drugs 0.000 description 31
- 229940079593 drug Drugs 0.000 description 16
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 7
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000000227 bioadhesive Substances 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 108010064719 Oxyhemoglobins Proteins 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 4
- 229960003086 naltrexone Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960004207 fentanyl citrate Drugs 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 238000003677 abuse test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229940087828 buprenex Drugs 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- -1 but not limited to Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940053209 suboxone Drugs 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Sheets, Magazines, And Separation Thereof (AREA)
- Friction Gearing (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83272506P | 2006-07-21 | 2006-07-21 | |
| US83272606P | 2006-07-21 | 2006-07-21 | |
| US832726P | 2006-07-21 | ||
| US832725P | 2006-07-21 | ||
| US83950406P | 2006-08-23 | 2006-08-23 | |
| US839504P | 2006-08-23 | ||
| PCT/US2007/016634 WO2008011194A2 (en) | 2006-07-21 | 2007-07-23 | Transmucosal delivery devices with enhanced uptake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2577390T3 true ES2577390T3 (es) | 2016-07-14 |
Family
ID=38819378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07796992.1T Active ES2577390T3 (es) | 2006-07-21 | 2007-07-23 | Dispositivos de administración transmucosa con mayor captación |
Country Status (22)
| Country | Link |
|---|---|
| US (13) | US20100015183A1 (enExample) |
| EP (3) | EP3067044B1 (enExample) |
| JP (2) | JP5448814B2 (enExample) |
| KR (2) | KR101230804B1 (enExample) |
| CN (2) | CN101511337B (enExample) |
| AU (1) | AU2007275581B2 (enExample) |
| BR (2) | BR122020000250B8 (enExample) |
| CA (1) | CA2658585C (enExample) |
| DK (1) | DK2054031T3 (enExample) |
| ES (1) | ES2577390T3 (enExample) |
| HR (1) | HRP20160405T1 (enExample) |
| HU (1) | HUE027395T2 (enExample) |
| IL (2) | IL196529A (enExample) |
| MX (1) | MX2009000745A (enExample) |
| NO (3) | NO340668B1 (enExample) |
| NZ (2) | NZ574361A (enExample) |
| PL (1) | PL2054031T3 (enExample) |
| RS (1) | RS54764B1 (enExample) |
| RU (3) | RU2504377C2 (enExample) |
| SI (1) | SI2054031T1 (enExample) |
| WO (1) | WO2008011194A2 (enExample) |
| ZA (1) | ZA200900485B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| RU2504377C2 (ru) * | 2006-07-21 | 2014-01-20 | БайоДеливери Сайенсиз Интэнэшнл, Инк. | Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли |
| WO2008036299A2 (en) | 2006-09-20 | 2008-03-27 | Monosol Rx Llc | Edible water-soluble film containing a foam reducing flavoring agent |
| US8298583B2 (en) | 2007-10-19 | 2012-10-30 | Monosol Rx, Llc | Film delivery system for tetrahydrolipstatin |
| US20110189259A1 (en) * | 2008-06-23 | 2011-08-04 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
| US8282954B2 (en) | 2008-12-15 | 2012-10-09 | Monosol Rx, Llc | Method for manufacturing edible film |
| DK2952191T3 (en) | 2009-06-12 | 2018-12-10 | Sunovion Pharmaceuticals Inc | Sublingual apomorphine |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| JP5819949B2 (ja) | 2010-06-10 | 2015-11-24 | ミダテック リミテッド | ナノ粒子フィルム送達システム |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| CA3115378A1 (en) | 2010-12-16 | 2012-06-21 | Sunovion Pharmaceuticals Inc. | Sublingual films comprising apomorphine and an organic base |
| WO2012104834A1 (en) * | 2011-02-03 | 2012-08-09 | Pharmedica Ltd. | New oral dissolving films for insulin administration, for treating diabetes |
| CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| EA033256B1 (ru) * | 2011-08-18 | 2019-09-30 | Байоделивери Сайенсиз Интернэшнл, Инк. | Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина |
| KR102078044B1 (ko) | 2011-09-19 | 2020-02-17 | 오렉쏘 에이비 | 오피오이드 의존증의 치료를 위한 남용-방지성 약학 조성물 |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| HK1203365A1 (en) * | 2011-12-21 | 2015-10-30 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| JP6279547B2 (ja) | 2012-04-17 | 2018-02-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| MX360665B (es) | 2012-05-02 | 2018-11-13 | Orexo Ab | Nueva composición de alfentanilo para el tratamiento del dolor agudo. |
| ES2654189T3 (es) | 2012-09-12 | 2018-02-12 | Boston Scientific Scimed, Inc. | Revestimiento adhesivo anti-migración para stent |
| CN105636616A (zh) | 2013-08-08 | 2016-06-01 | 波士顿科学国际有限公司 | 防止支架移位的可溶性或可降解粘合剂聚合物 |
| US9918981B2 (en) | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| US9839611B2 (en) | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| WO2015038327A1 (en) | 2013-09-10 | 2015-03-19 | Insys Pharma, Inc. | Sublingual buprenorphine spray |
| US9867818B2 (en) | 2013-09-10 | 2018-01-16 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US10617686B2 (en) | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| JP2017519803A (ja) | 2014-07-08 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 舌下ナロキソンスプレー |
| US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US20160144528A1 (en) * | 2014-11-25 | 2016-05-26 | Biodelivery Sciences International, Inc. | Patch devices, methods and apparatus for forming, and testing pharmaceutical agent delivery patch devices |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| JP7211706B2 (ja) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法 |
| US20170065580A1 (en) * | 2015-09-09 | 2017-03-09 | Biodelivery Sciences International, Inc. | Methods of safely transitioning a subject to buprenorphine |
| PL3381448T3 (pl) * | 2015-11-25 | 2025-04-14 | Tbm Company | Błona hemostatyczna i do ochrony ran w jamie ustnej |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| CN105997955B (zh) | 2016-06-28 | 2017-09-12 | 力品药业（厦门）有限公司 | 一种帕洛诺司琼口腔膜剂及其制备方法 |
| JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 経皮薬剤送達の装置及び方法 |
| KR101912380B1 (ko) | 2017-03-15 | 2018-10-26 | (주)바이오일레븐 | 프로바이오틱스의 방출 및 프로바이오틱스 효소 활성의 유지를 위한 점막점착성 장치 |
| EP3691610A1 (en) | 2017-10-07 | 2020-08-12 | Zim Laboratories Limited | Process for the preparation of bi/multi-layer film, multi-layered film produced thereof and apparatus for producing such multi-layer films |
| EP3755310A4 (en) * | 2018-02-22 | 2021-05-19 | Avior, Inc. | TRANSMUCOSAL FILM COMPOSITION AND METHOD OF MANUFACTURING AND USING THEREOF |
| JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
| EP3863712A4 (en) * | 2018-10-11 | 2022-07-20 | Indivior UK Limited | Buprenorphine to treat respiratory depression |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| US11318107B2 (en) | 2019-02-22 | 2022-05-03 | Avior, Inc. | Pharmaceutical active-containing film delivery device for oral transmucosal administration |
| WO2021163529A2 (en) | 2020-02-13 | 2021-08-19 | Biodelivery Sciences International, Inc. | Methods of treatment with buprenorphine |
| US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| US20240050368A1 (en) * | 2022-08-14 | 2024-02-15 | Patrick Hunter Young | Oral active agent delivery system for animals and method |
| CN116712415A (zh) * | 2023-07-07 | 2023-09-08 | 力品药业(厦门)股份有限公司 | 一种多奈哌齐口溶膜及其制备方法 |
Family Cites Families (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB981372A (en) | 1960-05-04 | 1965-01-27 | Pfizer Ltd | Pharmaceutical formulations for oral administration to animals |
| US3640741A (en) | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| GB2042888B (en) | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
| US4713239A (en) | 1979-05-29 | 1987-12-15 | Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr | Antianginal film and method of treating ischemic heart disease |
| US4285934A (en) | 1979-07-13 | 1981-08-25 | Tinnell James E | Treatment for herpes virus |
| JPS56100714A (en) | 1980-01-16 | 1981-08-12 | Teijin Ltd | Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane |
| US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
| US4381296A (en) | 1980-06-23 | 1983-04-26 | Tinnell James E | Treatment for herpes virus |
| JPS5758615A (en) | 1980-09-26 | 1982-04-08 | Nippon Soda Co Ltd | Film agnent and its preparation |
| JPS5770816A (en) * | 1980-10-17 | 1982-05-01 | Ono Pharmaceut Co Ltd | Multilayered film preparation of prostagladin of prolonged action |
| JPS57110254A (en) | 1980-12-29 | 1982-07-09 | Teijin Ltd | Coating agent of injured membrane part of oral cavity |
| AU8533582A (en) | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
| CH653550A5 (de) | 1981-10-20 | 1986-01-15 | Sandoz Ag | Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich. |
| US4518721A (en) | 1982-03-26 | 1985-05-21 | Richardson-Vicks Inc. | Hydrophilic denture adhesive |
| JPS5948409A (ja) | 1982-09-10 | 1984-03-19 | Teikoku Seiyaku Kk | 矯正的歯牙移動促進剤 |
| CA1208558A (en) | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
| JPS604120A (ja) | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
| JPS60116630A (ja) | 1983-11-29 | 1985-06-24 | Nitto Electric Ind Co Ltd | 口腔内製剤 |
| GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4713246A (en) | 1984-03-19 | 1987-12-15 | Bristol-Myers Company | Etoposide oral dosage form |
| US4740365A (en) | 1984-04-09 | 1988-04-26 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
| US5288498A (en) | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| ATE95430T1 (de) | 1984-12-22 | 1993-10-15 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster. |
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| JPS61280423A (ja) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | 口腔内粘膜貼付剤 |
| JPH0653659B2 (ja) | 1985-07-22 | 1994-07-20 | ニチバン株式会社 | 粘膜付着製剤 |
| GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
| JPS6256420A (ja) | 1985-09-05 | 1987-03-12 | Teijin Ltd | フイルム状付着性製剤 |
| JPH07553B2 (ja) | 1985-12-09 | 1995-01-11 | 佐藤製薬株式会社 | フイルム状製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| JPH0729915B2 (ja) | 1986-02-01 | 1995-04-05 | 帝國製薬株式会社 | シ−ト状口腔内貼付剤 |
| US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
| CH668187A5 (de) | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | Therapeutisches system mit systemischer wirkung. |
| US5196202A (en) | 1986-09-01 | 1993-03-23 | Teikoku Seiyaku Kabushiki Kaisha | Sustained release dosage form |
| JPH0794384B2 (ja) | 1986-09-01 | 1995-10-11 | 帝国製薬株式会社 | 徐放性口腔内用製剤 |
| US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| JPH0744940B2 (ja) | 1986-12-24 | 1995-05-17 | ライオン株式会社 | 口腔貼付用基材 |
| DE3714074A1 (de) | 1987-04-28 | 1988-11-10 | Hoechst Ag | Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage |
| US4867970A (en) | 1987-05-21 | 1989-09-19 | E. R. Squibb & Sons, Inc. | Moistureless oral drug delivery formulation and method for preparing same |
| JPS63310818A (ja) | 1987-06-12 | 1988-12-19 | Sato Seiyaku Kk | シ−ト状口腔粘膜付着製剤 |
| US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
| US5059189A (en) | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
| JPS6471812A (en) | 1987-09-11 | 1989-03-16 | Sekisui Chemical Co Ltd | Medical application agent |
| JP2635336B2 (ja) | 1987-09-30 | 1997-07-30 | 帝國製薬株式会社 | 徐放性口腔内用製剤 |
| US4990339A (en) * | 1987-11-16 | 1991-02-05 | H. B. Fuller Company | Dermal treatment film |
| US5064654A (en) * | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| JP2685055B2 (ja) | 1988-03-08 | 1997-12-03 | 帝國製薬株式会社 | シコン含有口腔粘膜貼付剤 |
| US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
| US5081158A (en) | 1988-05-02 | 1992-01-14 | Zila Pharmaceuticals, Inc. | Compositions and in situ methods for forming films on body tissue |
| US5081157A (en) | 1988-05-02 | 1992-01-14 | Zila Pharmaceuticals, Inc. | Compositions and in situ methods for forming films on body tissue |
| US5047244A (en) | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
| US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| JP2656338B2 (ja) | 1989-01-31 | 1997-09-24 | 日東電工株式会社 | 口腔粘膜貼付製剤 |
| JPH0645536B2 (ja) | 1989-01-31 | 1994-06-15 | 日東電工株式会社 | 口腔粘膜貼付剤および口腔粘膜貼付製剤 |
| US5750136A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
| JP2839164B2 (ja) * | 1989-12-25 | 1998-12-16 | 帝國製薬株式会社 | 消炎鎮痛貼付剤 |
| US5298258A (en) | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
| JP2879695B2 (ja) | 1990-02-22 | 1999-04-05 | 日本曹達株式会社 | 口腔内粘膜付着性フィルム製剤 |
| JP2930374B2 (ja) | 1990-06-28 | 1999-08-03 | 東亜医薬品工業株式会社 | 口腔内貼着型膜製剤 |
| US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5254345A (en) | 1991-10-11 | 1993-10-19 | Merck & Co., Inc. | Poly(orthocarbonate acetal) bioerodible polymers |
| US5298256A (en) | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5436701A (en) | 1992-06-19 | 1995-07-25 | Canon Kabushiki Kaisha | Image forming method, image forming apparatus and apparatus unit |
| GB2273044B (en) | 1992-12-02 | 1997-04-09 | Pacific Chem Co Ltd | Medicinal patches for percutaneous administration |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| EP0708627B1 (en) | 1993-07-09 | 2000-02-02 | Cygnus, Inc. | Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| WO1995005416A2 (en) | 1993-08-19 | 1995-02-23 | Cygnus Therapeutic Systems | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| FR2712807B1 (fr) | 1993-11-24 | 1996-02-23 | Vetoquinol Sa | Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale . |
| DE4341442C2 (de) | 1993-12-04 | 1998-11-05 | Lohmann Therapie Syst Lts | Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung |
| US5466465A (en) | 1993-12-30 | 1995-11-14 | Harrogate Holdings, Limited | Transdermal drug delivery system |
| US5679714A (en) | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| EP0751789B1 (en) | 1994-03-21 | 2001-11-07 | BROWN THOMSEN, John | Gel for treatment of skin diseases and for disinfection of the skin |
| WO1996000072A1 (en) | 1994-06-23 | 1996-01-04 | The Procter & Gamble Company | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
| DE4446600A1 (de) * | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
| DE69625549T2 (de) * | 1995-06-27 | 2003-05-15 | Kao Corp., Tokio/Tokyo | Pflaster mit wasserlöslicher Klebeschicht |
| US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
| JP2791317B2 (ja) | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | 多層フィルム製剤 |
| FR2742989B1 (fr) | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
| JP2000505090A (ja) * | 1996-07-11 | 2000-04-25 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | インドール選択的セロトニンアゴニストを含む包接錯体 |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| DE19652188C2 (de) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| ES2252865T3 (es) * | 1997-09-26 | 2006-05-16 | Noven Pharmaceuticals, Inc. | Composiciones bioadhesivas y metodos para la administracion topica de agentes activos. |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| BR9813826A (pt) * | 1997-12-22 | 2000-10-10 | Euro Celtique Sa | Potencial de uso abusivo de administração oral de opióide analgésico |
| AU773642C (en) | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
| US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| PT1079813E (pt) | 1998-04-29 | 2005-05-31 | Virotex Corp | Dispositivo transportador farmaceutico adequado para entrega de compostos farmaceuticos as superficies mucosas |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| CA2345808A1 (en) * | 1998-10-02 | 2000-04-13 | 3M Innovative Properties Company | Mucosal originated drug delivery systems and animal applications |
| ATE288256T1 (de) | 1999-01-14 | 2005-02-15 | Noven Pharma | Dermale zusammensetzungen |
| US20030170195A1 (en) | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6284262B1 (en) | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| DE19932603A1 (de) * | 1999-07-13 | 2001-01-25 | Gruenenthal Gmbh | Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| DE19960154A1 (de) * | 1999-12-14 | 2001-07-12 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie |
| US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US6719997B2 (en) * | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
| US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| EA004876B1 (ru) * | 2000-02-08 | 2004-08-26 | Эро-Селтик, С.А. | Устойчивые к порче композиции опиоидных агонистов для перорального введения |
| EP1284736A2 (en) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
| ATE359840T1 (de) | 2001-02-09 | 2007-05-15 | Hager & Werken Gmbh & Co Kg | Injektionsspritze |
| US20020160043A1 (en) * | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| WO2002087482A1 (en) | 2001-05-01 | 2002-11-07 | Euro-Celtique | Abuse resistant opioid containing transdermal systems |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| NZ530971A (en) | 2001-08-06 | 2004-08-27 | Euro Celtique S | Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
| US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
| US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| US20030194420A1 (en) * | 2002-04-11 | 2003-10-16 | Richard Holl | Process for loading a drug delivery device |
| AU2003234395B2 (en) | 2002-05-13 | 2008-01-24 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid solid dosage form |
| MXPA04012333A (es) | 2002-06-10 | 2005-02-25 | Euro Celtique Sa | Sistemas de colocacion de dispositivos de liberacion transdermica para prevenir el uso incorrecto de los agentes activos contenidos en los mismos. |
| SI1530469T1 (sl) | 2002-08-20 | 2009-06-30 | Euro Celtique Sa | Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze |
| AU2003286796A1 (en) * | 2002-10-31 | 2004-06-07 | Umd, Inc. | Therapeutic compositions for drug delivery to and through covering epithelia |
| US20050013845A1 (en) | 2002-11-12 | 2005-01-20 | Warren Stephen L. | Adhesive bioerodible ocular drug delivery system |
| US20040110781A1 (en) * | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
| MXPA05006334A (es) | 2002-12-13 | 2005-08-26 | Euro Celtique Sa | Dosis de buprenorfina transdermica para analgesia. |
| US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
| US20040191301A1 (en) | 2003-03-27 | 2004-09-30 | Van Duren Albert Philip | Transdermal device having a phase change material |
| US20040213828A1 (en) | 2003-04-23 | 2004-10-28 | Smith David J. | Pain relief lollipop compositions and methods |
| EP1641441B1 (en) | 2003-04-30 | 2014-03-12 | Purdue Pharma L.P. | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| US20040219195A1 (en) | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| JP5137286B2 (ja) * | 2003-06-10 | 2013-02-06 | 帝國製薬株式会社 | フェンタニル含有口腔粘膜貼付剤 |
| KR20060037234A (ko) | 2003-07-11 | 2006-05-03 | 마쯔시다덴기산교 가부시키가이샤 | 광픽업용 렌즈장치 및 이를 이용한 정보기록 재생장치 |
| CA2535846A1 (en) | 2003-08-15 | 2005-02-24 | Qlt Usa, Inc. | Adhesive bioerodible transmucosal drug delivery system |
| US20050042281A1 (en) * | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| US20080317828A1 (en) | 2003-09-24 | 2008-12-25 | Kazuyoshi Furusawa | Fentanyl compound-containing edible patch to be applied to oral mucosa |
| AU2004285505B2 (en) | 2003-10-28 | 2010-12-23 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device |
| EP1677771A2 (en) | 2003-10-30 | 2006-07-12 | Alza Corporation | Transdermal analgesic systems having reduced abuse potential |
| DE602004005076T2 (de) | 2003-12-09 | 2007-11-15 | Euro-Celtique S.A. | Co-extrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür |
| EP1711159B1 (en) | 2003-12-30 | 2013-03-20 | Durect Corporation | Solid implants containing a block copolymer for controlled release of a gnrh compound |
| PL2074989T3 (pl) | 2004-02-23 | 2014-05-30 | Euro Celtique Sa | Odporne na nadużywanie transdermalne urządzenie do podawania opioidu |
| EP1584335A3 (en) | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
| US20060051413A1 (en) * | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
| AU2005286733B2 (en) | 2004-09-23 | 2009-11-05 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US7827983B2 (en) | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
| DE102005007859A1 (de) | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
| GB0514043D0 (en) | 2005-07-08 | 2005-08-17 | Arakis Ltd | Fentanyl formulation |
| AU2006326377B2 (en) * | 2005-12-13 | 2010-10-07 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| RU2504377C2 (ru) | 2006-07-21 | 2014-01-20 | БайоДеливери Сайенсиз Интэнэшнл, Инк. | Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| CA2664986C (en) | 2006-10-02 | 2015-09-22 | Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh | Non-mucoadhesive film dosage forms |
| GB0620661D0 (en) | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| US20100010031A1 (en) | 2007-02-09 | 2010-01-14 | Yum Ii Su | Transoral dosage forms comprising sufentanil and naloxone |
| GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| US20110189259A1 (en) | 2008-06-23 | 2011-08-04 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| EA033256B1 (ru) * | 2011-08-18 | 2019-09-30 | Байоделивери Сайенсиз Интернэшнл, Инк. | Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина |
| US9901539B2 (en) * | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
-
2007
- 2007-07-23 RU RU2009106177/15A patent/RU2504377C2/ru active IP Right Revival
- 2007-07-23 HR HRP20160405TT patent/HRP20160405T1/hr unknown
- 2007-07-23 BR BR122020000250A patent/BR122020000250B8/pt active IP Right Grant
- 2007-07-23 CA CA2658585A patent/CA2658585C/en active Active
- 2007-07-23 WO PCT/US2007/016634 patent/WO2008011194A2/en not_active Ceased
- 2007-07-23 AU AU2007275581A patent/AU2007275581B2/en not_active Ceased
- 2007-07-23 JP JP2009520865A patent/JP5448814B2/ja not_active Expired - Fee Related
- 2007-07-23 CN CN2007800319087A patent/CN101511337B/zh not_active Expired - Fee Related
- 2007-07-23 EP EP16163659.2A patent/EP3067044B1/en active Active
- 2007-07-23 NZ NZ574361A patent/NZ574361A/en not_active IP Right Cessation
- 2007-07-23 KR KR1020097003532A patent/KR101230804B1/ko not_active Expired - Fee Related
- 2007-07-23 DK DK07796992.1T patent/DK2054031T3/en active
- 2007-07-23 NZ NZ594545A patent/NZ594545A/xx not_active IP Right Cessation
- 2007-07-23 HU HUE07796992A patent/HUE027395T2/hu unknown
- 2007-07-23 ES ES07796992.1T patent/ES2577390T3/es active Active
- 2007-07-23 PL PL07796992.1T patent/PL2054031T3/pl unknown
- 2007-07-23 CN CN201310524341.4A patent/CN103550136B/zh not_active Expired - Fee Related
- 2007-07-23 BR BRPI0714712A patent/BRPI0714712B8/pt not_active IP Right Cessation
- 2007-07-23 US US11/817,915 patent/US20100015183A1/en not_active Abandoned
- 2007-07-23 SI SI200731766A patent/SI2054031T1/sl unknown
- 2007-07-23 EP EP19165171.0A patent/EP3566692A1/en not_active Withdrawn
- 2007-07-23 RS RS20160294A patent/RS54764B1/sr unknown
- 2007-07-23 KR KR1020127018611A patent/KR101329496B1/ko not_active Expired - Fee Related
- 2007-07-23 MX MX2009000745A patent/MX2009000745A/es active IP Right Grant
- 2007-07-23 EP EP07796992.1A patent/EP2054031B1/en active Active
-
2009
- 2009-01-15 IL IL196529A patent/IL196529A/en active IP Right Grant
- 2009-01-19 NO NO20090278A patent/NO340668B1/no not_active IP Right Cessation
- 2009-01-21 ZA ZA2009/00485A patent/ZA200900485B/en unknown
-
2011
- 2011-07-15 US US13/184,306 patent/US8147866B2/en active Active
-
2012
- 2012-03-06 US US13/413,112 patent/US20120164191A1/en not_active Abandoned
- 2012-07-02 IL IL220722A patent/IL220722A/en active IP Right Grant
-
2013
- 2013-04-09 JP JP2013081427A patent/JP5689144B2/ja not_active Expired - Fee Related
- 2013-09-06 RU RU2013141051/15A patent/RU2013141051A/ru unknown
-
2015
- 2015-06-22 US US14/746,168 patent/US20150366793A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/198,961 patent/US9597288B2/en active Active
- 2016-07-18 US US15/212,912 patent/US9655843B2/en active Active
-
2017
- 2017-02-10 US US15/429,385 patent/US20170312218A1/en not_active Abandoned
- 2017-03-14 NO NO20170380A patent/NO344719B1/no not_active IP Right Cessation
- 2017-04-11 US US15/484,682 patent/US20170216278A1/en not_active Abandoned
- 2017-11-01 US US15/801,302 patent/US20190111048A9/en not_active Abandoned
-
2019
- 2019-04-25 US US16/394,647 patent/US20190365739A1/en not_active Abandoned
- 2019-06-10 RU RU2019118034A patent/RU2019118034A/ru unknown
-
2020
- 2020-03-06 NO NO20200273A patent/NO20200273A1/no not_active Application Discontinuation
-
2021
- 2021-03-22 US US17/209,119 patent/US20210275520A1/en not_active Abandoned
-
2023
- 2023-07-03 US US18/346,474 patent/US20240066024A1/en not_active Abandoned
- 2023-09-25 US US18/473,524 patent/US20240156809A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2577390T3 (es) | Dispositivos de administración transmucosa con mayor captación | |
| US11135216B2 (en) | Sublingual and buccal film compositions | |
| US10821074B2 (en) | Sublingual and buccal film compositions | |
| US20200315984A1 (en) | Sublingual and buccal film compositions | |
| ES2411179T3 (es) | Oblea de buprenorfina para la terapia de sustitución de drogas | |
| WO2007096906A2 (en) | Novel buccoadhesive compositions and process of preparation thereof | |
| ES2986170T3 (es) | Sistema terapéutico transmucosal que contiene agomelatina | |
| KR20250156085A (ko) | 레미마졸람을 포함하는 구강 점막 전달 시스템 | |
| KR20140120275A (ko) | 엔테카비르 함유 구강 붕해형 필름제제 | |
| WO2023069733A1 (en) | Pharmaceutical compositions with enhanced stability profiles | |
| EP4539824A2 (en) | Enhanced delivery epinephrine and prodrug compositions |